Developer docs
API playgroundTry for free, no card

Search company profiles

PackGene Biotech

Full company profile

uuid0000lpe

Namestring
PackGene Biotech
Legal namestring
PackGene Biotech Inc.
Websiteurl
packgene.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

PackGene Biotech Inc. is a privately held, Houston, Texas-based contract research and development/manufacturing organization (CRO/CDMO) that provides viral vector and nucleic acid solutions — primarily AAV (adeno-associated virus), lentivirus, mRNA/LNP, and plasmid DNA — to gene therapy and cell therapy developers. Founded in 2014 and operating from a 120,000 sqft facility, the company has delivered more than 50,000 projects to over 1,000 clients globally, including large biopharmaceutical companies (Biogen, Intellia, Decibel) and academic institutions (University of Sydney), and supports 25+ IND programs and 30+ IIT programs.

The company's service portfolio spans the full gene therapy manufacturing value chain, from vector design and plasmid preparation through research-grade and GMP-grade AAV/lentivirus production, mRNA synthesis and LNP formulation, and analytical/batch release testing. It is differentiated by three proprietary technology platforms — π-Alpha 293 (high-yield AAV production, up to 10-fold yield improvement and up to 1e+17vg per batch), π-Omega (high-yield plasmid production), and π-Icosa (AI-driven AAV capsid engineering) — plus the TP011 dual-plasmid system. Capabilities cover 70+ AAV serotypes and 40+ QC assays, and GMP plasmid is DMF-registered.

PackGene monetizes through project-based, quote-based fees across research, preclinical, and GMP service tiers, distributed via direct sales, an online ordering portal (order.packgene.com), global distributor partners, and regional websites for China, Japan, and South Korea. The go-to-market is sales-led, supplemented by heavy conference presence (ASGCT, AACR, BIO, Advanced Therapies Congress) and content marketing. The company has raised at least six funding rounds since 2019 — most recently a disclosed $14.1M Series C in December 2023 led by CMG-SDIC Capital Management — and is in active scale-up mode following its 2023 cGMP facility groundbreaking.

Short descriptiontext

PackGene Biotech is a Houston-based CRO/CDMO providing AAV, lentivirus, mRNA/LNP, and plasmid DNA manufacturing services to gene therapy developers, having delivered over 50,000 projects to 1,000+ clients globally from research through GMP.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersHouston, United States
HQ citystring
Houston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
viral vector manufacturing, AAV packaging services, gene therapy CRO, CDMO services, plasmid DNA production
Industry3 codes
PRIMARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
Product category
Gene Therapy CDMO Services
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1AAV Vector Services
TypeProfessional Services
Description

AAV packaging and production services for research grade, NHP grade, and GMP manufacturing. Revenue generated through project-based fees for vector design, production, purification, and quality control services.

packgene.com
2Lentivirus Services
TypeProfessional Services
Description

Lentivirus packaging and production services including express gene-to-lentivirus service and custom lentiviral plasmid design.

packgene.com
3mRNA and LNP Services
TypeProfessional Services
Description

Custom mRNA synthesis and mRNA-LNP development services from research grade through GMP production.

packgene.com
4Plasmid DNA Services
TypeProfessional Services
Description

Plasmid preparation and manufacturing services ranging from research grade to GMP, with scales from 100µg to 100g.

packgene.com
5AAV Testing and Analytical Services
TypeProfessional Services
Description

Comprehensive analytical testing services including mass photometry, genome titer by ddPCR, empty/full capsid ratio by AUC, genome integrity by CE, and genome sequencing by nanopore.

packgene.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1π-Alpha
Description

293 AAV High-yield Production Platform leveraging uniquely designed RC and helper plasmids, engineered production cell lines, and QbD optimizations to significantly enhance total AAV yield.

packgene.com
+2 more records
Core offering1 text field

PackGene Biotech is a contract research organization (CRO) and contract development and manufacturing organization (CDMO) specializing in cell and gene therapy solutions. The company provides AAV vector packaging, lentivirus production, custom mRNA/LNP synthesis, and plasmid DNA services from research grade through GMP manufacturing, supported by proprietary high-yield production platforms and comprehensive analytical characterization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • AAV production yield increased by up to 10-fold using π-Alpha platform
+3 more records
Product overview1 text field

PackGene Biotech is a world-leading CRO and CDMO offering comprehensive cell and gene therapy solutions. The company's integrated platform spans from vector design and construction to AAV, lentivirus, mRNA, and plasmid services, supporting early-stage drug discovery through GMP manufacturing. The portfolio centers on three proprietary technology platforms: π-Alpha 293 (high-yield AAV production), π-Omega (high-yield plasmid production), and π-Icosa (AI-powered AAV capsid engineering). Core service offerings include AAV production and packaging (research, NHP, and GMP grades), lentivirus packaging, custom mRNA and LNP services, and comprehensive analytical testing. The company operates a 120,000 sqft GMP facility in Houston, Texas, and has delivered over 50,000 projects to more than 1,000 clients globally.

Product and service30 records
1π-Alpha 293 AAV High-yield Production Platform
CategoryTechnology Platform
Description

A proprietary high-yield AAV production platform that amplifies AAV production by up to 10-fold, yielding up to 1e+17vg per batch. Used by gene therapy developers requiring scalable viral vector manufacturing.

2π-Omega Plasmid DNA High-yield Production Platform
CategoryTechnology Platform
Description

A proprietary high-yield plasmid DNA production platform that improves plasmid yield, quality, and biosafety. Used by gene therapy developers requiring GMP-grade plasmid manufacturing.

3π-Icosa AAV Serotype Screening Platform
CategoryTechnology Platform
Description

An AI-powered AAV capsid engineering platform that enhances AAV infectivity and specificity through screening and validation in animal models, supported by AI-driven predictions of novel capsid sequences. Used by gene therapy developers seeking enhanced tissue targeting and manufacturability.

4AAV Production Services
CategoryCRO Services
Description

Comprehensive AAV vector production services offering high-quality vectors with reliably low empty capsid content across 70+ serotypes with 40+ QC assays. For biopharma and academic gene therapy developers.

5AAV Packaging – Research Grade
CategoryCRO Services
Description

Research-grade AAV packaging with delivery in as little as 12 days from miniprep to purified virus, featuring high purity, low endotoxin levels, and minimal empty capsids. For academic and early-stage research programs.

6AAV Packaging – NHP Grade
CategoryCRO Services
Description

GMP-like AAV vectors for non-human primate studies with enhanced quality controls for preclinical toxicology studies. For biopharma preclinical programs.

7Express Gene-to-AAV Service
CategoryCRO Services
Description

Accelerated AAV production service enabling rapid transition from gene sequence to purified AAV vector. For researchers needing fast-turnaround AAV production.

8Off-the-Shelf AAV Products
CategoryCRO Services
Description

Pre-packaged AAV products including control AAV vectors available for immediate ordering. For research labs needing ready-to-use viral vectors.

9AAV Testing Services
CategoryAnalytical Services
Description

Comprehensive analytical testing for AAV vectors including mass photometry, genome titer by ddPCR, empty/full capsid ratio by AUC, genome integrity by CE, and genome sequencing by Nanopore. For gene therapy developers needing characterization and QC testing.

10Capsid Engineering
CategoryCRO Services
Description

Custom AAV capsid engineering services to develop novel capsids with enhanced tissue targeting, reduced immunogenicity, and improved therapeutic properties. For gene therapy researchers advancing novel AAV vectors.

11AAV Capsid Discovery Kits
CategoryCRO Services
Description

Pre-packaged kits for AAV capsid screening and discovery enabling rapid evaluation of capsid variants. For research labs conducting capsid selection studies.

12AAV Capsid & Gene Library Services
CategoryCRO Services
Description

Services for creating and screening custom AAV capsid and gene libraries for targeted applications. For gene therapy discovery programs.

13Lentivirus Packaging
CategoryCRO Services
Description

Lentiviral vector production with delivery in 8-12 business days, accurate titer via post-transduction qPCR, and enhanced safety features. For cell therapy developers and gene delivery researchers.

14Express Gene-to-Lentivirus Service
CategoryCRO Services
Description

Accelerated lentivirus production service for rapid gene delivery applications. For researchers needing fast turnaround on lentiviral vectors.

15Custom mRNA Service
CategoryCRO Services
Description

Custom mRNA synthesis with high-quality mRNA, full QC panel, custom scales, stability, and modifications for research and preclinical applications. For vaccine developers and gene therapy researchers.

16Custom mRNA-LNP Service
CategoryCRO Services
Description

mRNA encapsulation in lipid nanoparticles for enhanced stability, protected mRNA delivery, increased uptake, and reduced immunogenicity. For vaccine and gene therapy developers.

17mRNA and LNP Products
CategoryCRO Services
Description

Pre-formulated mRNA and LNP products available for immediate use in research and development. For research labs needing ready-to-use mRNA reagents.

18Fast mRNA Service for Gene Editing
CategoryCRO Services
Description

Rapid mRNA synthesis service optimized for gene editing applications including CRISPR components. For gene editing researchers.

19piVector Designer
CategoryVector Design Services
Description

Online vector design tool for designing AAV and lentivirus plasmids with application-specific elements. For researchers designing gene delivery constructs.

20AAV Plasmid Design and Construction
CategoryVector Design Services
Description

Custom AAV plasmid design and cloning services for efficient gene delivery constructs. For gene therapy developers needing customized plasmid backbones.

21Lentivirus Plasmid Design and Construction
CategoryVector Design Services
Description

Custom lentiviral plasmids for gene overexpression and silencing supporting CRISPR, shRNA, and miRNA applications. For gene therapy and functional genomics researchers.

22Plasmid Preparation
CategoryCRO Services
Description

Flexible plasmid preparation services from 100µg to 2g for research and preclinical grades. For research labs and biopharma developers.

23Preclinical Grade Plasmid
CategoryCDMO Services
Description

Higher purity plasmid DNA for preclinical studies with enhanced quality controls. For biopharma preclinical development programs.

24Process Development
CategoryCDMO Services
Description

AAV process development services for scalable manufacturing including cell line development, high-cell-density transfection, and robust purification process development. For gene therapy developers advancing to GMP manufacturing.

25AAV Analytical Development
CategoryCDMO Services
Description

Analytical method development and validation for AAV product characterization and release testing. For biopharma developers requiring regulatory-grade analytics.

26GMP Plasmid Manufacturing
CategoryCDMO Services
Description

cGMP plasmid production up to 200L with flexible scaling, isolated production lines, and advanced single-use technology. Over 10 years of expert plasmid manufacturing; DMF (Drug Master File) registered. For biopharma clinical and commercial programs.

27GMP AAV Manufacturing
CategoryCDMO Services
Description

High-productivity GMP AAV manufacturing with scalable production platform, cost-effective solutions with in-house GMP plasmid manufacturing and comprehensive release testing. For gene therapy developers in clinical and commercial stages.

28AAV One-Stop Solution
CategoryCDMO Services
Description

Integrated end-to-end AAV manufacturing from process development through GMP production including aseptic fill-finish and cell banking. For biopharma seeking a single CDMO partner for full AAV programs.

29GMP AAV Batch Release Testing
CategoryCDMO Services
Description

Comprehensive batch release testing services for GMP AAV products meeting regulatory requirements. For biopharma submitting IND or BLA filings.

30GMP mRNA & LNP
CategoryCDMO Services
Description

GMP manufacturing services for mRNA and LNP products supporting clinical and commercial applications. For vaccine developers and gene therapy programs.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-19
Description

PackGene Biotech and Kudo Biotechnology partnered to offer customized mRNA manufacturing services, combining PackGene's viral vector expertise with Kudo's specialized capabilities in mRNA development.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

VectorBuilder is a global CRO/CDMO offering AAV, lentivirus, mRNA, and plasmid services with proprietary vector design tools. It directly competes with PackGene across research-grade and GMP-grade gene therapy manufacturing, with overlapping customer bases in academic and biotech segments.

TypeDirect peer
Description

GenScript ProBio is the CDMO arm of GenScript offering cell and gene therapy services including AAV and lentivirus manufacturing, plasmid production, and GMP capabilities. It competes head-to-head with PackGene in the global gene therapy CDMO market with comparable service breadth from research to GMP.

TypeDirect peer
Description

Andelyn Biosciences is an AAV and lentivirus CDMO operating a 200,000+ sqft GMP facility in Columbus, Ohio. As a US-based gene therapy CDMO with comparable AAV focus, it competes with PackGene for the same biopharma and academic customers seeking GMP-grade viral vector manufacturing.

TypeDirect peer
Description

WuXi AppTec's Advanced Therapies Unit offers viral vector and cell therapy CDMO services including AAV and lentivirus manufacturing at scale. It competes with PackGene across the full gene therapy manufacturing value chain and is one of the largest global players in this segment.

5Vigene Biosciences (Charles River)
TypeDirect peer
Description

Vigene Biosciences, now part of Charles River Laboratories, specializes in AAV and lentivirus production services for gene therapy. Acquired by Charles River to scale its gene therapy CDMO offering, it directly overlaps with PackGene's core AAV/lentivirus service portfolio.

TypeBroad incumbent
Description

Lonza is one of the world's largest CDMOs with a significant cell and gene therapy business offering viral vector and cell therapy manufacturing. It competes with PackGene primarily for large commercial-stage GMP programs, offering broader scale and longer regulatory track record.

TypeBroad incumbent
Description

Catalent, recently acquired by Novo Holdings, operates large-scale gene therapy manufacturing facilities offering AAV and lentivirus production. As an established broad CDMO incumbent, it competes with PackGene for enterprise customers seeking integrated drug development and manufacturing solutions.

TypeBroad incumbent
Description

Charles River Laboratories is a large CRO/CDMO with viral vector manufacturing capabilities through its Vigene acquisition and broader cell and gene therapy services. It offers PackGene-comparable AAV/lentivirus services as part of a much wider preclinical and manufacturing portfolio.

TypeBroad incumbent
Description

Thermo Fisher Scientific acquired Brammer Bio to enter viral vector CDMO and offers AAV manufacturing as part of its pharma services portfolio. As a global pharma services giant, it competes with PackGene for large enterprise gene therapy sponsors.

10Resolian
TypeEmerging player
Description

Resolian is a specialist bioanalytical CRO offering gene therapy characterization services including AAV capsid analysis and impurity testing. It is a partial competitor and ecosystem partner to PackGene for analytical and testing services supporting gene therapy CMC.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PackGene Biotech

Gene Therapy CDMO Servicespackgene.com

PackGene Biotech is a Houston-based CRO/CDMO providing AAV, lentivirus, mRNA/LNP, and plasmid DNA manufacturing services to gene therapy developers, having delivered over 50,000 projects to 1,000+ clients globally from research through GMP.

What PackGene Biotech does

PackGene Biotech Inc. is a privately held, Houston, Texas-based contract research and development/manufacturing organization (CRO/CDMO) that provides viral vector and nucleic acid solutions — primarily AAV (adeno-associated virus), lentivirus, mRNA/LNP, and plasmid DNA — to gene therapy and cell therapy developers. Founded in 2014 and operating from a 120,000 sqft facility, the company has delivered more than 50,000 projects to over 1,000 clients globally, including large biopharmaceutical companies (Biogen, Intellia, Decibel) and academic institutions (University of Sydney), and supports 25+ IND programs and 30+ IIT programs.

The company's service portfolio spans the full gene therapy manufacturing value chain, from vector design and plasmid preparation through research-grade and GMP-grade AAV/lentivirus production, mRNA synthesis and LNP formulation, and analytical/batch release testing. It is differentiated by three proprietary technology platforms — π-Alpha 293 (high-yield AAV production, up to 10-fold yield improvement and up to 1e+17vg per batch), π-Omega (high-yield plasmid production), and π-Icosa (AI-driven AAV capsid engineering) — plus the TP011 dual-plasmid system. Capabilities cover 70+ AAV serotypes and 40+ QC assays, and GMP plasmid is DMF-registered.

PackGene monetizes through project-based, quote-based fees across research, preclinical, and GMP service tiers, distributed via direct sales, an online ordering portal (order.packgene.com), global distributor partners, and regional websites for China, Japan, and South Korea. The go-to-market is sales-led, supplemented by heavy conference presence (ASGCT, AACR, BIO, Advanced Therapies Congress) and content marketing. The company has raised at least six funding rounds since 2019 — most recently a disclosed $14.1M Series C in December 2023 led by CMG-SDIC Capital Management — and is in active scale-up mode following its 2023 cGMP facility groundbreaking.

PackGene Biotech firmographics

Firmographics
Name
PackGene Biotech
Legal name
PackGene Biotech Inc.
Website
https://packgene.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
51–100 employees
Short description
PackGene Biotech is a Houston-based CRO/CDMO providing AAV, lentivirus, mRNA/LNP, and plasmid DNA manufacturing services to gene therapy developers, having delivered over 50,000 projects to 1,000+ clients globally from research through GMP.
Ownership category
akta.pro rank

PackGene Biotech industry classification

Industry
Product category
Gene Therapy CDMO Services
akta.pro industry
PRIMARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Viral vector manufacturing
  • AAV packaging services
  • Gene therapy CRO
  • CDMO services
  • Plasmid DNA production

Where PackGene Biotech is headquartered

Location

Headquarters

HQ city
Houston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

PackGene Biotech business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. AAV Vector Services: AAV packaging and production services for research grade, NHP grade, and GMP manufacturing. Revenue generated through project-based fees for vector design, production, purification, and quality control services.
  2. Lentivirus Services: Lentivirus packaging and production services including express gene-to-lentivirus service and custom lentiviral plasmid design.
  3. mRNA and LNP Services: Custom mRNA synthesis and mRNA-LNP development services from research grade through GMP production.
  4. Plasmid DNA Services: Plasmid preparation and manufacturing services ranging from research grade to GMP, with scales from 100µg to 100g.
  5. AAV Testing and Analytical Services: Comprehensive analytical testing services including mass photometry, genome titer by ddPCR, empty/full capsid ratio by AUC, genome integrity by CE, and genome sequencing by nanopore.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

PackGene Biotech product offering

Product offering

Core offering

PackGene Biotech is a contract research organization (CRO) and contract development and manufacturing organization (CDMO) specializing in cell and gene therapy solutions. The company provides AAV vector packaging, lentivirus production, custom mRNA/LNP synthesis, and plasmid DNA services from research grade through GMP manufacturing, supported by proprietary high-yield production platforms and comprehensive analytical characterization.

Product overview

PackGene Biotech is a world-leading CRO and CDMO offering comprehensive cell and gene therapy solutions. The company's integrated platform spans from vector design and construction to AAV, lentivirus, mRNA, and plasmid services, supporting early-stage drug discovery through GMP manufacturing. The portfolio centers on three proprietary technology platforms: π-Alpha 293 (high-yield AAV production), π-Omega (high-yield plasmid production), and π-Icosa (AI-powered AAV capsid engineering). Core service offerings include AAV production and packaging (research, NHP, and GMP grades), lentivirus packaging, custom mRNA and LNP services, and comprehensive analytical testing. The company operates a 120,000 sqft GMP facility in Houston, Texas, and has delivered over 50,000 projects to more than 1,000 clients globally.

Differentiator

Problem solved

Functional benefit

Brands

  • π-Alpha: 293 AAV High-yield Production Platform leveraging uniquely designed RC and helper plasmids, engineered production cell lines, and QbD optimizations to significantly enhance total AAV yield.
  • π-Omega
  • π-Icosa

Products and services

  • π-Alpha 293 AAV High-yield Production Platform A proprietary high-yield AAV production platform that amplifies AAV production by up to 10-fold, yielding up to 1e+17vg per batch. Used by gene therapy developers requiring scalable viral vector manufacturing.
  • π-Omega Plasmid DNA High-yield Production Platform A proprietary high-yield plasmid DNA production platform that improves plasmid yield, quality, and biosafety. Used by gene therapy developers requiring GMP-grade plasmid manufacturing.
  • π-Icosa AAV Serotype Screening Platform An AI-powered AAV capsid engineering platform that enhances AAV infectivity and specificity through screening and validation in animal models, supported by AI-driven predictions of novel capsid sequences. Used by gene therapy developers seeking enhanced tissue targeting and manufacturability.
  • AAV Production Services Comprehensive AAV vector production services offering high-quality vectors with reliably low empty capsid content across 70+ serotypes with 40+ QC assays. For biopharma and academic gene therapy developers.
  • AAV Packaging – Research Grade Research-grade AAV packaging with delivery in as little as 12 days from miniprep to purified virus, featuring high purity, low endotoxin levels, and minimal empty capsids. For academic and early-stage research programs.
  • AAV Packaging – NHP Grade GMP-like AAV vectors for non-human primate studies with enhanced quality controls for preclinical toxicology studies. For biopharma preclinical programs.
  • Express Gene-to-AAV Service Accelerated AAV production service enabling rapid transition from gene sequence to purified AAV vector. For researchers needing fast-turnaround AAV production.
  • Off-the-Shelf AAV Products Pre-packaged AAV products including control AAV vectors available for immediate ordering. For research labs needing ready-to-use viral vectors.
  • AAV Testing Services Comprehensive analytical testing for AAV vectors including mass photometry, genome titer by ddPCR, empty/full capsid ratio by AUC, genome integrity by CE, and genome sequencing by Nanopore. For gene therapy developers needing characterization and QC testing.
  • Capsid Engineering Custom AAV capsid engineering services to develop novel capsids with enhanced tissue targeting, reduced immunogenicity, and improved therapeutic properties. For gene therapy researchers advancing novel AAV vectors.
  • AAV Capsid Discovery Kits Pre-packaged kits for AAV capsid screening and discovery enabling rapid evaluation of capsid variants. For research labs conducting capsid selection studies.
  • AAV Capsid & Gene Library Services Services for creating and screening custom AAV capsid and gene libraries for targeted applications. For gene therapy discovery programs.
  • Lentivirus Packaging Lentiviral vector production with delivery in 8-12 business days, accurate titer via post-transduction qPCR, and enhanced safety features. For cell therapy developers and gene delivery researchers.
  • Express Gene-to-Lentivirus Service Accelerated lentivirus production service for rapid gene delivery applications. For researchers needing fast turnaround on lentiviral vectors.
  • Custom mRNA Service Custom mRNA synthesis with high-quality mRNA, full QC panel, custom scales, stability, and modifications for research and preclinical applications. For vaccine developers and gene therapy researchers.
  • Custom mRNA-LNP Service mRNA encapsulation in lipid nanoparticles for enhanced stability, protected mRNA delivery, increased uptake, and reduced immunogenicity. For vaccine and gene therapy developers.
  • mRNA and LNP Products Pre-formulated mRNA and LNP products available for immediate use in research and development. For research labs needing ready-to-use mRNA reagents.
  • Fast mRNA Service for Gene Editing Rapid mRNA synthesis service optimized for gene editing applications including CRISPR components. For gene editing researchers.
  • piVector Designer Online vector design tool for designing AAV and lentivirus plasmids with application-specific elements. For researchers designing gene delivery constructs.
  • AAV Plasmid Design and Construction Custom AAV plasmid design and cloning services for efficient gene delivery constructs. For gene therapy developers needing customized plasmid backbones.
  • Lentivirus Plasmid Design and Construction Custom lentiviral plasmids for gene overexpression and silencing supporting CRISPR, shRNA, and miRNA applications. For gene therapy and functional genomics researchers.
  • Plasmid Preparation Flexible plasmid preparation services from 100µg to 2g for research and preclinical grades. For research labs and biopharma developers.
  • Preclinical Grade Plasmid Higher purity plasmid DNA for preclinical studies with enhanced quality controls. For biopharma preclinical development programs.
  • Process Development AAV process development services for scalable manufacturing including cell line development, high-cell-density transfection, and robust purification process development. For gene therapy developers advancing to GMP manufacturing.
  • AAV Analytical Development Analytical method development and validation for AAV product characterization and release testing. For biopharma developers requiring regulatory-grade analytics.
  • GMP Plasmid Manufacturing cGMP plasmid production up to 200L with flexible scaling, isolated production lines, and advanced single-use technology. Over 10 years of expert plasmid manufacturing; DMF (Drug Master File) registered. For biopharma clinical and commercial programs.
  • GMP AAV Manufacturing High-productivity GMP AAV manufacturing with scalable production platform, cost-effective solutions with in-house GMP plasmid manufacturing and comprehensive release testing. For gene therapy developers in clinical and commercial stages.
  • AAV One-Stop Solution Integrated end-to-end AAV manufacturing from process development through GMP production including aseptic fill-finish and cell banking. For biopharma seeking a single CDMO partner for full AAV programs.
  • GMP AAV Batch Release Testing Comprehensive batch release testing services for GMP AAV products meeting regulatory requirements. For biopharma submitting IND or BLA filings.
  • GMP mRNA & LNP GMP manufacturing services for mRNA and LNP products supporting clinical and commercial applications. For vaccine developers and gene therapy programs.

Quantifiable outcome

  • AAV production yield increased by up to 10-fold using π-Alpha platform
  • +3 more outcomes

Companies that use PackGene Biotech

Customer profile

Named customers4 records

Segments2 records

Ideal customer profiles2 records

PackGene Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

PackGene Biotech partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Kudo BiotechnologycoreStrategic or Co-development Partner · 19 September 2023PackGene Biotech and Kudo Biotechnology partnered to offer customized mRNA manufacturing services, combining PackGene's viral vector expertise with Kudo's specialized capabilities in mRNA development.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

PackGene Biotech competitors and assessment

Company assessment

Direct peers

  • VectorBuilder: VectorBuilder is a global CRO/CDMO offering AAV, lentivirus, mRNA, and plasmid services with proprietary vector design tools. It directly competes with PackGene across research-grade and GMP-grade gene therapy manufacturing, with overlapping customer bases in academic and biotech segments.
  • GenScript ProBio: GenScript ProBio is the CDMO arm of GenScript offering cell and gene therapy services including AAV and lentivirus manufacturing, plasmid production, and GMP capabilities. It competes head-to-head with PackGene in the global gene therapy CDMO market with comparable service breadth from research to GMP.
  • Andelyn Biosciences: Andelyn Biosciences is an AAV and lentivirus CDMO operating a 200,000+ sqft GMP facility in Columbus, Ohio. As a US-based gene therapy CDMO with comparable AAV focus, it competes with PackGene for the same biopharma and academic customers seeking GMP-grade viral vector manufacturing.
  • WuXi Advanced Therapies Unit: WuXi AppTec's Advanced Therapies Unit offers viral vector and cell therapy CDMO services including AAV and lentivirus manufacturing at scale. It competes with PackGene across the full gene therapy manufacturing value chain and is one of the largest global players in this segment.
  • Vigene Biosciences (Charles River): Vigene Biosciences, now part of Charles River Laboratories, specializes in AAV and lentivirus production services for gene therapy. Acquired by Charles River to scale its gene therapy CDMO offering, it directly overlaps with PackGene's core AAV/lentivirus service portfolio.

Broad incumbents

  • Lonza Cell & Gene: Lonza is one of the world's largest CDMOs with a significant cell and gene therapy business offering viral vector and cell therapy manufacturing. It competes with PackGene primarily for large commercial-stage GMP programs, offering broader scale and longer regulatory track record.
  • Catalent (Novo Holdings): Catalent, recently acquired by Novo Holdings, operates large-scale gene therapy manufacturing facilities offering AAV and lentivirus production. As an established broad CDMO incumbent, it competes with PackGene for enterprise customers seeking integrated drug development and manufacturing solutions.
  • Charles River Laboratories: Charles River Laboratories is a large CRO/CDMO with viral vector manufacturing capabilities through its Vigene acquisition and broader cell and gene therapy services. It offers PackGene-comparable AAV/lentivirus services as part of a much wider preclinical and manufacturing portfolio.
  • Thermo Fisher Scientific (Patheon/Brammer Bio): Thermo Fisher Scientific acquired Brammer Bio to enter viral vector CDMO and offers AAV manufacturing as part of its pharma services portfolio. As a global pharma services giant, it competes with PackGene for large enterprise gene therapy sponsors.

Emerging players

  • Resolian: Resolian is a specialist bioanalytical CRO offering gene therapy characterization services including AAV capsid analysis and impurity testing. It is a partial competitor and ecosystem partner to PackGene for analytical and testing services supporting gene therapy CMC.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights7 records

Customer concentration

PackGene Biotech social profiles

Digital presence

PackGene Biotech compliance and trust

Trust signal

Compliance1 record

PackGene Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PackGene Biotech leadership team

Management profile

Number of profiles

Profiles5 records

PackGene Biotech funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PackGene Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PackGene Biotech

What does PackGene Biotech do?

PackGene Biotech is a contract research organization (CRO) and contract development and manufacturing organization (CDMO) specializing in cell and gene therapy solutions. The company provides AAV vector packaging, lentivirus production, custom mRNA/LNP synthesis, and plasmid DNA services from research grade through GMP manufacturing, supported by proprietary high-yield production platforms and comprehensive analytical characterization.

Is PackGene Biotech a public or private company?

PackGene Biotech is a private company. It is classified as venture growth investor backed and is currently operating.

When was PackGene Biotech founded?

PackGene Biotech was founded in 2016. It employs 51 to 100 people.

Where is PackGene Biotech based?

PackGene Biotech is headquartered in Houston, United States, in the North America region.

How does PackGene Biotech make money?

Five revenue lines are on record. AAV Vector Services are the primary driver. The others are lentivirus Services, mRNA and LNP Services, plasmid DNA Services and AAV Testing and Analytical Services.

Who are PackGene Biotech's main competitors?

Direct peers on record are VectorBuilder, GenScript ProBio, Andelyn Biosciences, WuXi Advanced Therapies Unit and Vigene Biosciences (Charles River). Broad incumbents are Lonza Cell & Gene, Catalent (Novo Holdings), Charles River Laboratories and Thermo Fisher Scientific (Patheon/Brammer Bio). Resolian is listed as an emerging player.

Does PackGene Biotech have an API?

No public API is recorded for PackGene Biotech.

What industry is PackGene Biotech in?

PackGene Biotech's product category is Gene Therapy CDMO Services. Its primary akta.pro industry code is HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO, with a secondary code of HLAGAGAB, Gene Therapy CDMO (Viral Vector Manufacturing).

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageFrost & Sullivan presents the “Global Gene Therapy Crdmo Technology Innovation Leadership Award” to PackGene Biotech Inc.Frost & Sullivan awarded PackGene Biotech the Global Gene Therapy CRDMO Technology Innovation Leadership Award at its 2026 New Investment Event in Shanghai. The award recognizes PackGene's proprietary AAV production platforms, including the π-Alpha™ 293 cell line and AI-driven R&D, and its GMP-compliant manufacturing facilities.NewsfileFrost & Sullivan presents the "GLOBAL GENE THERAPY CRDMO TECHNOLOGY INNOVATION LEADERSHIP AWARD" to PackGene Biotech Inc.Frost & Sullivan awarded PackGene Biotech the Global Gene Therapy CRDMO Technology Innovation Leadership Award at its 2026 New Investment Event in Shanghai. The award recognizes PackGene's proprietary AAV production platforms, including the π-Alpha™ 293 cell line and AI-driven R&D, and its GMP-compliant manufacturing facilities.FinancialContent Business PageFrost & Sullivan presents the "GLOBAL GENE THERAPY CRDMO TECHNOLOGY INNOVATION LEADERSHIP AWARD" to PackGene Biotech Inc.Frost & Sullivan awarded PackGene Biotech the Global Gene Therapy CRDMO Technology Innovation Leadership Award at its 2026 New Investment Event in Shanghai. The award recognizes PackGene's proprietary AAV production platforms, including the π-Alpha™ 293 cell line and AI-driven R&D, and its GMP-compliant manufacturing facilities.Grand View ResearchViral Capsid Development MarketThe global viral capsid development market was valued at USD 314.3 million in 2025 and is projected to grow to USD 684.5 million by 2033, at a CAGR of 10.4%, driven by increasing demand for gene therapies, rising viral vector R&D, and advancements in capsid engineering including AI-driven design. North America held the largest market share (48.3%) in 2025, while Asia Pacific is expected to be the fastest-growing region with a CAGR of 13.59%. The report identifies key players including PackGene Biotech Inc., Sartorius AG, Revvity, and VectorBuilder, among others, competing through proprietary vector engineering, strong clinical pipelines, and application-specific viral capsid solutions.PR NewswirePackGene to Present Advances in Scalable AAV Manufacturing, Analytical Innovation, and Novel Capsid Engineering at ASGCT 2026PackGene Biotech announced six presentations at the American Society of Gene & Cell Therapy 29th Annual Meeting in Boston, May 11–15, showcasing advances in AAV vector development, scalable manufacturing, and analytical characterization. The presentations address key industry bottlenecks including residual DNA impurities, empty/full variability, and manufacturing consistency through upstream innovation, purification improvements, and novel capsid engineering. The company's stated mission is to make gene therapy affordable through higher-quality vector production at scale.GenengnewsSmarter AAVs Drive Gene Therapy’s Next ChapterResearchers and biotechnology companies are advancing adeno-associated virus (AAV) technology to address key limitations in gene therapy, including manufacturing scalability, vector analytics, and tissue-targeting precision. Innovations span scalable bioprocessing workflows, advanced analytical methods such as multiplex droplet digital PCR and LC-MS, capsid engineering to reduce therapeutic doses, and AI-powered design platforms like PackGene's π-Icosa platform that simultaneously optimize tissue targeting and manufacturability. Several companies including Catalent, Charles River Laboratories, and Asimov have introduced production platforms designed to accelerate the path from discovery to clinical-scale manufacturing, with the goal of making gene therapy more commercially viable and accessible.PackgeneAdvancing AAV Gene Therapy: Integrated CMC Strategy for the New Era of Scalable ManufacturingThis article is a comprehensive industry whitepaper from PackGene examining the CMC (Chemistry, Manufacturing, and Controls) challenges in AAV gene therapy manufacturing, including upstream processing, downstream purification, analytical characterization, and formulation hurdles. The paper advocates for an integrated, platform-based CMC strategy grounded in Quality by Design (QbD) principles, orthogonal analytics, and early comparability planning to transition from proof-of-concept to commercial-scale production. PackGene positions itself as an end-to-end CDMO partner offering integrated AAV manufacturing services from preclinical development through clinical supply, leveraging its proprietary π-Omega plasmid DNA high-yield platform and scalable suspension technologies.GlobeNewswirePortage Biotech and Compedica Stock-for-Stock ExchangePortage Biotech and Compedica Holdings entered a stock-for-stock exchange on June 5, 2025, with Portage issuing 625,000 shares at $8.00 for 1,165,501 Compedica shares, valued at $4.29 each. The transaction, worth $5 million, gives Compedica a 27.4% stake in Portage. Portage will use at least 50% of any future equity funding to buy more Compedica shares.PR NewswirePackGene Biotech and Kudo Biotechnology Partner to Offer Customized mRNA Manufacturing ServicesPackGene Biotech and Kudo Biotechnology announced a partnership to provide customized mRNA manufacturing services for drug and vaccine development. The collaboration covers end-to-end workflow from plasmid DNA and cell banking to mRNA synthesis, LNP encapsulation, and fill-finish under GMP guidelines. Both companies aim to meet growing demand for mRNA production.